The global therapeutic nuclear medicine market, valued at USD 1.32 billion in 2024, is poised for significant growth over the next decade. Projected to expand at a Compound Annual Growth Rate (CAGR) of 4.1% from 2024 to 2034, the market is expected to reach a valuation of USD 1.97 billion by 2034.
The growth of the therapeutic nuclear medicine market is driven by increasing adoption of targeted radiopharmaceutical therapies for cancer and other chronic diseases. These therapies offer precision treatment by delivering radioactive isotopes directly to affected tissues, minimizing damage to surrounding healthy cells.
Key factors fueling market expansion include advancements in nuclear medicine technology, rising prevalence of cancer and cardiovascular diseases, and increasing investment in radiopharmaceutical R&D. Regulatory support for innovative therapies and expanding applications in personalized medicine are further boosting the market outlook.
As healthcare systems worldwide focus on precision oncology and tailored treatments, the therapeutic nuclear medicine market is set for sustained growth, offering promising solutions for complex medical conditions.
Key Growth Drivers
The growth of the therapeutic nuclear medicine market is influenced by several factors:
- Increasing Incidence of Cancer: The rising number of cancer cases globally is a significant driver, as therapeutic nuclear medicine plays a crucial role in treating various cancers, particularly thyroid cancer.
- Advancements in Nuclear Medicine Technology: Innovations in radiopharmaceuticals and imaging techniques are enhancing the effectiveness and safety of nuclear medicine therapies.
Market Dynamics
- The market is characterized by the use of radioactive materials for both diagnostic and therapeutic purposes, with a growing emphasis on personalized medicine.
- Increased awareness and acceptance of nuclear medicine therapies among healthcare providers and patients are contributing to market expansion.
Regional Insights
- North America is expected to dominate the therapeutic nuclear medicine market due to high healthcare spending, advanced medical infrastructure, and strong research and development activities.
- Emerging markets in Asia-Pacific may experience significant growth driven by increasing healthcare investments and a rising burden of cancer-related diseases.
Market Players Shaping the Outlook of the Therapeutic Nuclear Medicine Market
The therapeutic nuclear medicine industry’s dynamics are changing, and the key market players are vying for the majority stake in the competitive environment. Market players are implementing organic marketing techniques such as mergers and acquisitions, collaborations, and product launches to acquire a competitive advantage.
Top players produce the majority of nuclear medicine treatment products. Industry leaders have built their position in the market by investing more in research and having a better distribution system.
Recent technological developments in nuclear imaging modalities and the introduction of innovative pharmaceuticals into the global market have given the industry a huge boost. Continued and persistent research and development activities that result in betterment in new application areas are pushing market expansion.
Recent Developments in the Therapeutic Nuclear Medicine Market
- In February 2024, The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held a Mid-Winter Meeting in Orlando, drawing over 700 professionals from various fields to learn from experts and enhance patient care.
- In January 2024, The University of Texas MD Anderson Cancer Center partnered with the International Atomic Energy Agency (IAEA) to establish an IAEA Collaborating Centre, directing to improve global radiation oncology, radiation physics, radiology, nuclear medicine, and nutrition, focusing on healthcare.
- In January 2024, BARC’s Radiation Medicine Research Centre (RMRC) in Kolkata launched advanced Nuclear Medicine services, including FDG PET/CT imaging. The center aspires to provide affordable, advanced diagnostic and therapeutic services in India’s Eastern and northeastern states while providing medical and science graduate training and R&D efforts in Nuclear Medicine imaging and radiopharmaceutical development.
- In July 2023, The International BRICS Expert Forum on Nuclear Medicine in Moscow attracted over 200 representatives from Russia, Brazil, India, China, and South Africa to discuss progressions in radionuclide diagnostics, disease treatment, and medical device development.
Key Companies in the Therapeutic Nuclear Medicine Market
- Bayer AG
- GE Healthcare
- Novartis AG
- Cardinal Health Inc.
- Mallinckrodt plc.
- Lantheus Medical Imaging Inc.
- Bracco Imaging S.p.A
- Eckert & Ziegler
- Curium Pharma
- International Isotopes Idaho, Inc.
- Medi-Radiopharma Co., Ltd.
A Full Report Overview
Key Segments
By Treatment Type:
- Radium-223
- Iodine-131
- Leutitium-177
- Yttrium-90
- Samarium-153
- Strontium-89
- Rhenium-188+Rhenium-186
- Erbium- 169
- Phosphorous-32
- Others
By Indication:
- Prostate Cancer
- Painful Bone Metastases
- Thyroid Cancer
- Neuroblastoma
- Synovitis
- Non-Hodgkin’s Lymphoma
- Hepatic Metastases
- Brain Tumour
- Others
By Distribution Channel:
- Hospitals
- Ambulatory Surgical Centers
- Cancer Research Institutes
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube